Order Article Reprints

Padovan M, Eoli M, Pellerino A, Rizzato S, Caserta C, Simonelli M, Michiara M, Caccese M, Anghileri E, Cerretti G, et al. Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO). Cancers. 2021; 13(11):2773. https://doi.org/10.3390/cancers13112773

Padovan, Marta, Marica Eoli, Alessia Pellerino, Simona Rizzato, Claudia Caserta, Matteo Simonelli, Maria Michiara, Mario Caccese, Elena Anghileri, Giulia Cerretti, and et al. 2021. "Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO)" Cancers 13, no. 11: 2773. https://doi.org/10.3390/cancers13112773

Padovan, M., Eoli, M., Pellerino, A., Rizzato, S., Caserta, C., Simonelli, M., Michiara, M., Caccese, M., Anghileri, E., Cerretti, G., Rudà, R., Zagonel, V., & Lombardi, G. (2021). Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO). Cancers, 13(11), 2773. https://doi.org/10.3390/cancers13112773